摘要糖皮质激素及其他免疫抑制剂是非感染性葡萄膜炎的主要治疗方案，新型生物可降解缓释玻璃体植入剂临床应用前景广阔，生物制剂显示出独特疗效。目前应用的局部糖皮质激素包括氟西奈德植入剂、地塞米松玻璃体植入剂等。免疫抑制剂包括抗代谢药甲氨蝶呤、硫唑嘌呤、霉酚酸酯等；T细胞抑制剂环孢霉素、他克莫司、雷帕霉素等；烷化剂环磷酰胺、苯丁酸氮芥等。生物制剂包括抗肿瘤坏死因子制剂英夫利昔单抗、阿达木单抗、依那西普、戈利木单抗、赛妥珠单抗等；白细胞介素受体拮抗剂阿那白滞素、康纳单抗、托珠单抗等；选择性B淋巴细胞抑制剂利妥昔单抗；选择性T淋巴细胞抑制剂阿巴西普等。不同药物各有其适用范围和不良反应，根据不同患者病情选择合适治疗方案、控制疾病进展、减少并发症的发生尤为重要。 (国际眼科纵览，2021, 45：89-98)

abstractsGlucocorticoids and other immunosuppressants are the primary therapeutic options for non-infectious uveitis. Novel biodegradable sustained-release vitreous implants are promising for extensive clinical applications, and biological agents have shown unique efficacy. The currently applied topical glucocorticoid implants include fluocinolone acetonide implant, dexamethasone vitreous implant, etc. The immunosuppressants include antimetabolites methotrexate, azathioprine, and mycophenolate mofetil, etc.; T cell inhibitors cyclosporine, tacrolimus, and rapamycin, etc.; and alkylating agents cyclophosphamide and chlorambucil, etc. The biological agents include anti-tumor necrosis factor agents infliximab, adalimumab, etanercept, golimumab, and certolizumab, etc.; interleukin receptor antagonists anakinra, canalizumab, and tocilizumab, etc.; selective B lymphocyte inhibitor rituximab; and selective T lymphocyte inhibitor abatacept, etc. Different agents have their respective scopes of application and adverse reactions. It is particularly important to select a treatment regimen appropriate for the patient’s condition, to control disease progression, and to reduce complications.( Int Rev Ophthalmol, 2021, 45: 89-98)